Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 23

Cited In for PubMed (Select 19036157)

1.

Status of epigenetic chromatin modification enzymes and esophageal squamous cell carcinoma risk in northeast Indian population.

Singh V, Singh LC, Singh AP, Sharma J, Borthakur BB, Debnath A, Rai AK, Phukan RK, Mahanta J, Kataki AC, Kapur S, Saxena S.

Am J Cancer Res. 2015 Feb 15;5(3):979-99. eCollection 2015.

2.

Calcineurin-mediated YB-1 dephosphorylation regulates CCL5 expression during monocyte differentiation.

Alidousty C, Rauen T, Hanssen L, Wang Q, Alampour-Rajabi S, Mertens PR, Bernhagen J, Floege J, Ostendorf T, Raffetseder U.

J Biol Chem. 2014 Aug 1;289(31):21401-12. doi: 10.1074/jbc.M114.562991. Epub 2014 Jun 19.

3.

YB-1 regulates Sox2 to coordinately sustain stemness and tumorigenic properties in a phenotypically distinct subset of breast cancer cells.

Jung K, Wu F, Wang P, Ye X, Abdulkarim BS, Lai R.

BMC Cancer. 2014 May 9;14:328. doi: 10.1186/1471-2407-14-328.

4.

YB-1 transforms human mammary epithelial cells through chromatin remodeling leading to the development of basal-like breast cancer.

Davies AH, Reipas KM, Pambid MR, Berns R, Stratford AL, Fotovati A, Firmino N, Astanehe A, Hu K, Maxwell C, Mills GB, Dunn SE.

Stem Cells. 2014 Jun;32(6):1437-50. doi: 10.1002/stem.1707.

5.

The p90 ribosomal S6 kinase (RSK) inhibitor BI-D1870 prevents gamma irradiation-induced apoptosis and mediates senescence via RSK- and p53-independent accumulation of p21WAF1/CIP1.

Neise D, Sohn D, Stefanski A, Goto H, Inagaki M, Wesselborg S, Budach W, Stühler K, Jänicke RU.

Cell Death Dis. 2013 Oct 17;4:e859. doi: 10.1038/cddis.2013.386.

6.

Targeted therapy for breast cancer prevention.

den Hollander P, Savage MI, Brown PH.

Front Oncol. 2013 Sep 23;3:250. doi: 10.3389/fonc.2013.00250. Review.

7.

YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells.

Mantwill K, Naumann U, Seznec J, Girbinger V, Lage H, Surowiak P, Beier D, Mittelbronn M, Schlegel J, Holm PS.

J Transl Med. 2013 Sep 18;11:216. doi: 10.1186/1479-5876-11-216.

8.

Insulin activates RSK (p90 ribosomal S6 kinase) to trigger a new negative feedback loop that regulates insulin signaling for glucose metabolism.

Smadja-Lamère N, Shum M, Déléris P, Roux PP, Abe J, Marette A.

J Biol Chem. 2013 Oct 25;288(43):31165-76. doi: 10.1074/jbc.M113.474148. Epub 2013 Sep 13.

9.

Inherited and acquired alterations in development of breast cancer.

Rizzolo P, Silvestri V, Falchetti M, Ottini L.

Appl Clin Genet. 2011 Nov 14;4:145-58. doi: 10.2147/TACG.S13226. Print 2011.

10.

Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1).

Reipas KM, Law JH, Couto N, Islam S, Li Y, Li H, Cherkasov A, Jung K, Cheema AS, Jones SJ, Hassell JA, Dunn SE.

Oncotarget. 2013 Feb;4(2):329-45.

11.

Insights into the inhibition of the p90 ribosomal S6 kinase (RSK) by the flavonol glycoside SL0101 from the 1.5 Å crystal structure of the N-terminal domain of RSK2 with bound inhibitor.

Utepbergenov D, Derewenda U, Olekhnovich N, Szukalska G, Banerjee B, Hilinski MK, Lannigan DA, Stukenberg PT, Derewenda ZS.

Biochemistry. 2012 Aug 21;51(33):6499-510. doi: 10.1021/bi300620c. Epub 2012 Aug 6.

12.

The role of MAPK in drug-induced kidney injury.

Cassidy H, Radford R, Slyne J, O'Connell S, Slattery C, Ryan MP, McMorrow T.

J Signal Transduct. 2012;2012:463617. doi: 10.1155/2012/463617. Epub 2012 Mar 12.

13.

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation.

Mendoza MC, Er EE, Blenis J.

Trends Biochem Sci. 2011 Jun;36(6):320-8. doi: 10.1016/j.tibs.2011.03.006. Epub 2011 Apr 30. Review.

14.

YB-1 evokes susceptibility to cancer through cytokinesis failure, mitotic dysfunction and HER2 amplification.

Davies AH, Barrett I, Pambid MR, Hu K, Stratford AL, Freeman S, Berquin IM, Pelech S, Hieter P, Maxwell C, Dunn SE.

Oncogene. 2011 Aug 25;30(34):3649-60. doi: 10.1038/onc.2011.82. Epub 2011 Mar 21.

15.

Impact of oncogenic K-RAS on YB-1 phosphorylation induced by ionizing radiation.

Toulany M, Schickfluss TA, Eicheler W, Kehlbach R, Schittek B, Rodemann HP.

Breast Cancer Res. 2011 Mar 10;13(2):R28. doi: 10.1186/bcr2845.

16.

Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases.

Cargnello M, Roux PP.

Microbiol Mol Biol Rev. 2011 Mar;75(1):50-83. doi: 10.1128/MMBR.00031-10. Review. Erratum in: Microbiol Mol Biol Rev. 2012 Jun;76(2):496.

17.

Identification of Y-box binding protein 1 as a core regulator of MEK/ERK pathway-dependent gene signatures in colorectal cancer cells.

Jürchott K, Kuban RJ, Krech T, Blüthgen N, Stein U, Walther W, Friese C, Kiełbasa SM, Ungethüm U, Lund P, Knösel T, Kemmner W, Morkel M, Fritzmann J, Schlag PM, Birchmeier W, Krueger T, Sperling S, Sers C, Royer HD, Herzel H, Schäfer R.

PLoS Genet. 2010 Dec 2;6(12):e1001231. doi: 10.1371/journal.pgen.1001231.

18.

Molecular decoy to the Y-box binding protein-1 suppresses the growth of breast and prostate cancer cells whilst sparing normal cell viability.

Law JH, Li Y, To K, Wang M, Astanehe A, Lambie K, Dhillon J, Jones SJ, Gleave ME, Eaves CJ, Dunn SE.

PLoS One. 2010 Sep 10;5(9). pii: e12661. doi: 10.1371/journal.pone.0012661.

19.

Suppression of Her2/neu expression through ILK inhibition is regulated by a pathway involving TWIST and YB-1.

Kalra J, Sutherland BW, Stratford AL, Dragowska W, Gelmon KA, Dedhar S, Dunn SE, Bally MB.

Oncogene. 2010 Dec 2;29(48):6343-56. doi: 10.1038/onc.2010.366. Epub 2010 Sep 13.

20.

Molecular composition of staufen2-containing ribonucleoproteins in embryonic rat brain.

Maher-Laporte M, Berthiaume F, Moreau M, Julien LA, Lapointe G, Mourez M, DesGroseillers L.

PLoS One. 2010 Jun 28;5(6):e11350. doi: 10.1371/journal.pone.0011350.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk